For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

29th Aug 13

Pharmaxis Announces Delay to French Pricing for Bronchitol

Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for  the cystic fibrosis treatment.

Read full media release - pdf
13th Aug 13

Australian Medical Media Release: Simplified PBS Listing for Bronchitol

The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF).

Read full media release - pdf
18th Jul 13

Pharmaxis Announces Improved PBS Listing of Bronchitol

Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has received approval for simplified access to Bronchitol® for the treatment of cystic fibrosis (CF) under the Australian government’s  Pharmaceutical Benefits Scheme (PBS) in a decision that brings criteria for reimbursement in line with current clinical practice.

Pharmaxis has been advised of a positive decision on its application to the Pharmaceutical Benefits Advisory Committee (PBAC) to change the wording of the PBS listing for Bronchitol, removing a requirement for patients to demonstrate a 10% increase in a spirometric measure of lung function in order to secure continued PBS reimbursement.


Read full media release - pdf